title: IDN-6556 Idun Pharmaceuticals Inc.
abstract: IDN-6556 is a lead compound from a class of small-molecule caspase protease inhibitors, and is currently under development by Idun as a potential treatment for acute alcoholic and infectious hepatitis. In October 2003, a phase II trial of IDN-6556 began in 100 patients undergoing liver transplantation.
authors.affiliation: Cedars-Sinai Medical Center, Liver Transplant Dept, 8635 W Third Street, Suite 590W, Los Angeles, CA 90048, USA. Fred.Poordad@cshs.org
authors.forename: F Fred
authors.initials: FF
authors.lastname: Poordad
mesh_terms: D000818:Animals; D061945:Caspase Inhibitors; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D010421:Pentanoic Acids / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
chemical_list: C487112:3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid; D061945:Caspase Inhibitors; D010421:Pentanoic Acids